RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
RedHill Biopharma has licensed RHB-102 (Bekinda®) to Hyloris Pharmaceuticals for commercialization worldwide excluding North America. The deal includes an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues.
RHB-102 is a once-daily, extended-release oral tablet formulation of ondansetron in development for multiple indications. The UK MHRA has provided a clear pathway for a Marketing Authorization Application, potentially making it the first oral 24-hour extended-release ondansetron for treating chemotherapy/radiotherapy-induced nausea and vomiting.
RedHill will continue development for FDA approval in the U.S., while Hyloris handles development, regulatory and commercialization activities in its territories. The global antiemetics market was valued at approximately $7.5 billion in 2023 with expected growth at 6% CAGR through 2030.
RedHill Biopharma ha concesso in licenza RHB-102 (Bekinda®) a Hyloris Pharmaceuticals per la commercializzazione in tutto il mondo, esclusa l'America del Nord. L'accordo include un pagamento iniziale e fino a 60 milioni di dollari in potenziali pagamenti legati a traguardi, oltre a royalties sui ricavi che possono arrivare fino ai venti percento a metà.
RHB-102 è una formulazione di compresse orali a rilascio prolungato di ondansetron da assumere una volta al giorno, in fase di sviluppo per molteplici indicazioni. L'MHRA del Regno Unito ha fornito un percorso chiaro per una domanda di autorizzazione al marketing, rendendolo potenzialmente il primo ondansetron orale a rilascio prolungato di 24 ore per il trattamento della nausea e del vomito indotti da chemioterapia/radioterapia.
RedHill continuerà lo sviluppo per l'approvazione della FDA negli Stati Uniti, mentre Hyloris gestirà lo sviluppo, le attività regolatorie e di commercializzazione nei suoi territori. Il mercato globale degli antiemetici è stato valutato circa 7,5 miliardi di dollari nel 2023 con una crescita prevista del 6% CAGR fino al 2030.
RedHill Biopharma ha licenciado RHB-102 (Bekinda®) a Hyloris Pharmaceuticals para su comercialización en todo el mundo, excluyendo América del Norte. El acuerdo incluye un pago inicial y hasta 60 millones de dólares en pagos por hitos potenciales, además de regalías de hasta un porcentaje medio de veintitantos sobre los ingresos.
RHB-102 es una formulación de tabletas orales de liberación prolongada de ondansetron que se toma una vez al día y está en desarrollo para múltiples indicaciones. La MHRA del Reino Unido ha proporcionado un camino claro para una solicitud de autorización de comercialización, lo que podría convertirlo en el primer ondansetron oral de liberación prolongada de 24 horas para tratar la náusea y el vómito inducidos por quimioterapia/radioterapia.
RedHill continuará el desarrollo para la aprobación de la FDA en EE. UU., mientras que Hyloris se encargará del desarrollo, la regulación y las actividades de comercialización en sus territorios. El mercado global de antieméticos se valoró en aproximadamente 7,5 mil millones de dólares en 2023 con un crecimiento esperado del 6% CAGR hasta 2030.
레드힐 바이오파마는 힐로리스 제약에 RHB-102 (베킨다®)의 전 세계 상용화 라이센스를 부여했습니다. 이 계약에는 선불금과 최대 6천만 달러의 잠재적 이정표 지급이 포함되며, 수익에 대한 중간 20%의 로열티도 포함됩니다.
RHB-102는 여러 적응증을 위해 개발 중인 하루에 한 번 복용하는 장시간 방출 경구 정제 형태의 온단세트론입니다. 영국 MHRA는 마케팅 승인 신청을 위한 명확한 경로를 제공하여, 이는 화학요법/방사선요법으로 유발된 메스꺼움 및 구토 치료를 위한 최초의 24시간 경구 장시간 방출 온단세트론이 될 수 있습니다.
레드힐은 미국에서 FDA 승인을 위한 개발을 계속하는 반면, 힐로리스는 자신의 지역에서 개발, 규제 및 상용화 활동을 처리합니다. 2023년 글로벌 항구토제 시장은 약 75억 달러로 평가되었으며, 2030년까지 연평균 6% 성장할 것으로 예상됩니다.
RedHill Biopharma a accordé une licence pour RHB-102 (Bekinda®) à Hyloris Pharmaceuticals pour la commercialisation dans le monde entier, à l'exception de l'Amérique du Nord. L'accord comprend un paiement initial et jusqu'à 60 millions de dollars de paiements potentiels liés à des jalons, ainsi que des redevances pouvant atteindre un pourcentage moyen de vingt pour cent sur les revenus.
RHB-102 est une formulation de comprimés oraux à libération prolongée d'ondansétron à prendre une fois par jour, en cours de développement pour plusieurs indications. L'MHRA du Royaume-Uni a fourni une voie claire pour une demande d'autorisation de mise sur le marché, ce qui pourrait en faire le premier ondansétron oral à libération prolongée de 24 heures pour traiter les nausées et vomissements induits par la chimiothérapie/radiothérapie.
RedHill continuera le développement pour l'approbation de la FDA aux États-Unis, tandis que Hyloris s'occupera des activités de développement, réglementaires et de commercialisation dans ses territoires. Le marché mondial des antiémétiques a été évalué à environ 7,5 milliards de dollars en 2023, avec une croissance prévue de 6 % CAGR jusqu'en 2030.
RedHill Biopharma hat RHB-102 (Bekinda®) an Hyloris Pharmaceuticals zur weltweiten Vermarktung, ausgenommen Nordamerika, lizenziert. Der Deal umfasst eine Vorauszahlung und bis zu 60 Millionen Dollar an potenziellen Meilensteinzahlungen sowie bis zu zwanzig Prozent Lizenzgebühren auf die Einnahmen.
RHB-102 ist eine einmal täglich einzunehmende orale Tablettenformulierung von Ondansetron, die für mehrere Indikationen entwickelt wird. Die MHRA des Vereinigten Königreichs hat einen klaren Weg für einen Antrag auf Marktzulassung geschaffen, wodurch es möglicherweise das erste orale 24-Stunden-Extended-Release-Ondansetron zur Behandlung von durch Chemotherapie/Radiotherapie induzierter Übelkeit und Erbrechen werden könnte.
RedHill wird die Entwicklung für die FDA-Zulassung in den USA fortsetzen, während Hyloris die Entwicklung, regulatorischen und kommerziellen Aktivitäten in seinen Gebieten übernimmt. Der globale Markt für Antiemetika wurde 2023 auf etwa 7,5 Milliarden Dollar geschätzt, mit einem erwarteten Wachstum von 6% CAGR bis 2030.
- Licensing deal worth up to $60 million in milestone payments plus royalties up to mid-20s percent
- Clear regulatory pathway from UK MHRA for Marketing Authorization Application
- Potential to be first oral 24-hour extended-release ondansetron for CINV/RINV
- Successful Phase 3 GUARD study for gastroenteritis and Phase 2 IBS-D study completed
- Global antiemetics market valued at $7.5 billion with 6% CAGR expected
- Milestone payments contingent on achieving commercial targets
- RedHill still needs to complete certain manufacturing activities
- FDA approval in the U.S. not yet secured
Insights
RedHill Biopharma's exclusive licensing agreement with Hyloris for RHB-102 (Bekinda®) represents a potentially transformative deal for this micro-cap company. With RedHill's current market capitalization of just $6.27 million, the agreement's potential value of up to $60 million in milestone payments plus up to mid-20s percent royalties could significantly alter the company's financial trajectory.
The royalty structure is particularly noteworthy in today's biopharmaceutical licensing landscape. Typical royalty rates for late-stage assets generally range from 10-15%, making RedHill's negotiated rate of up to mid-20s percent exceptionally favorable. While the exact upfront payment wasn't disclosed, this deal provides RedHill with a capital infusion while offloading development and commercialization costs outside North America.
RHB-102's once-daily formulation addresses a significant unmet need in the $7.5 billion antiemetics market. Current ondansetron formulations typically require multiple daily doses, creating adherence challenges for cancer patients already managing complex medication regimens. The 24-hour extended-release profile could provide meaningful clinical differentiation in the competitive antiemetics landscape.
This agreement follows a strategic pattern for RedHill, coming after their recent Bayer-funded Phase 2 study of opaganib and darolutamide in advanced prostate cancer. These partnerships suggest management is effectively leveraging their pipeline assets to generate non-dilutive capital while retaining valuable rights in the lucrative North American market.
The multi-indication development strategy for RHB-102 (CINV/RINV, gastroenteritis, IBS-D, and potentially PONV) creates multiple commercialization pathways, diversifying risk and expanding market potential. With positive Phase 3 data for gastroenteritis and Phase 2 data for IBS-D already in hand, these additional indications represent significant upside beyond the oncology support applications.
The positive MHRA feedback provides regulatory validation and potentially accelerates the path to commercialization in the UK and potentially other markets. For investors, this deal transforms RedHill's risk profile by providing near-term capital while maintaining substantial long-term upside through milestone payments and royalties. Given RedHill's current market valuation, the market appears to be significantly undervaluing this asset and the company's broader pipeline potential.
RedHill's licensing deal with Hyloris for RHB-102 represents a potentially transformative transaction for a company with a market capitalization of just $6.27 million. The agreement's potential value of $60 million plus royalties is nearly 10 times RedHill's current market cap, suggesting the market may be significantly undervaluing this asset and the company's potential.
The royalty structure deserves particular attention. The negotiated rate of up to mid-20s percent substantially exceeds typical biopharmaceutical licensing agreements, which generally range from 8-15% for late-stage assets. This premium rate likely reflects RHB-102's differentiated profile and substantial market potential across multiple indications.
In the $7.5 billion antiemetics market, RHB-102 addresses critical limitations of current standard-of-care treatments. Conventional ondansetron formulations require multiple daily doses (typically three times daily), creating adherence challenges for cancer patients already managing complex medication regimens and suffering from treatment-related fatigue. The once-daily extended-release formulation represents meaningful innovation in a market segment that hasn't seen significant delivery advancements in years.
Market segmentation analysis reveals multiple substantial opportunities. The CINV/RINV segment alone represents approximately $4 billion of the antiemetics market. The additional indications—gastroenteritis, IBS-D, and potentially PONV—expand the addressable market considerably, with IBS-D affecting approximately 30 million Americans alone.
Hyloris brings valuable commercialization capabilities to this partnership as a specialty pharmaceutical company focused on value-added reformulations. Their European presence and reformulation expertise make them well-positioned to navigate the regulatory pathway opened by the positive MHRA feedback. With manufacturing activities as the primary remaining hurdle before submission, commercial launch in the UK could potentially occur within 12-18 months.
For RedHill, this agreement provides critical non-dilutive capital while retaining rights to the lucrative North American market. The deal significantly extends their cash runway and reduces overall development risk. Coming after their Bayer collaboration for opaganib, this second major partnership validates management's strategy of leveraging their pipeline through strategic alliances while maintaining core assets.
The primary risks include potential regulatory delays, manufacturing challenges, and the competitive landscape evolution. However, the positive MHRA feedback and successful Phase 2/3 studies substantially mitigate regulatory risk, making this an unusually de-risked opportunity for a company of RedHill's size.
- Hyloris will pay
- Recent positive
-
- The global antiemetics drugs market size was valued at approximately
- Positive results from the successful

Under the terms of the Agreement, Hyloris will pay
RHB-102 is a once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, a 5-HT3 antagonist in advanced development for oncology support, acute gastroenteritis and gastritis[1], and diarrhea-predominant irritable bowel syndrome (IBS-D) at two dose strengths: 12mg and 24mg.
"Ondansetron ER will be a valuable addition to supportive care in oncology and post-surgical settings, where sustained relief from nausea is essential," said Thomas Jacobsen, Co-Chief Executive Officer of Hyloris. "We are committed to delivering innovative solutions that enhance patient comfort and streamline therapy, especially in areas where reducing treatment burden can make a meaningful impact. We look forward to collaborating with
"Our new partners at Hyloris share our vision of RHB-102's significant potential, and we look forward to working with them to bring RHB-102 to patients worldwide," said Dror Ben-Asher, CEO of
Recent positive advice from the
The global antiemetics drugs market size was valued at approximately
About RHB-102 (Bekinda®):
RHB-102 is a proprietary, once-daily, bimodal extended-release, oral tablet formulation of ondansetron, a 5-HT3 antagonist, targeting oncology support, acute gastroenteritis and gastritis, and IBS-D at two dose strengths: 12mg and 24mg.
Positive results from the successful
About Hyloris Pharmaceuticals SA
Hyloris (EBR: HYL) is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.
Hyloris is based in Liège,
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[5]. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications with U.S. government and academic collaborations for development for radiation and chemical exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program study in prostate cancer in combination with Bayer's darolutamide; (ii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential
More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the potential arrangement and relationship with Hyloris. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the Company will not benefit from the agreement with Hyloris as currently anticipated; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding
Company contact:
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
Category: Corporate
[1] Acute gastroenteritis and gastritis are characterized by inflammation of the mucus membranes of the gastrointestinal tract, most commonly caused by viral infection, with symptoms including nausea, vomiting, diarrhea and abdominal pain.
[2] Antiemetics Drugs Market Size & Share Analysis Report 2030,
[3] Plasse TF, Barton G, Davidson E, et al. Bimodal release ondansetron improves stool consistency and symptomatology in diarrhea-predominant irritable bowel syndrome: A randomized, double-blind trial. Am J Gastroenterol 2020;115:1466-73.
[4] Silverman RA, House SL, Meltzer AC, et al. Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial. JAMA Netw Open. 2019;2(11):e1914988. doi:10.1001/jamanetworkopen.2019.14988
[5] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.
Logo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg
SOURCE RedHill Biopharma Ltd.